|
规格 |
|
| Accession Number: | NM_020377.2 |
| Assay Entry: | Cell-based beta lactamase reporter gene |
| Cell Line: | CHO-K1 |
| Cell State: | Dividing Cells |
| Druggable Target: | GPCRs |
| Gene Symbol: | CysLT2 |
| Population Status: | Single Cell Clone Origin |
| Product Line: | GeneBLAzer® |
| Reporter Gene: | BLA (Beta-Lactamase) |
| System Type: | GeneBLAzer™ |
| Target Entry: | CysLT2 |
| Technique: | FRET |
| Detection Method: | Fluorescent |
|
储存 |
|
|
Contents: K1721 GeneBLAzer® CysLT2-NFAT-bla CHO-K1 cells (LiveBLAzer™-FRET B⁄G Loading Kit, Solution D and other materials are required separately; please refer to the protocol). Includes: • GeneBLAzer® CysLT2-NFAT-bla CHO-K1 cells • GeneBLAzer® CysLT2-NFAT-bla CHO-K1 Assay Protocol • Certificate of Analysis Storage: The GeneBLAzer® CysLT2-NFAT-bla CHO-K1 cells are shipped on dry ice and should be stored in liquid nitrogen immediately upon receipt. |
|
描述 |
GeneBLAzer® CysLT2-NFAT-bla CHO-K1 cells contain the human Cysteinyl receptor (CysLT2) stably integrated into the CellSensor® NFAT-bla CHO-K1 cell line. CellSensor® NFAT-bla CHO-K1 cells (Cat. no. K1534) contain a beta-lactamase reporter gene under control of the Nuclear Factor of Activated T-cells (NFAT) response element.
The GeneBLAzer® CysLT2-NFAT-bla CHO-K1 cells are functionally validated for Z' and EC50 concentrations of LTD4. In addition, GeneBLAzer® CysLT2-NFAT-bla CHO-K1 cells have been tested for assay performance under variable conditions. These data are found in the Validation & Assay Performance Summary.
Cysteinyl leukotrienes play a role in the patho-physiology of numerous inflammatory disorders, including chronic asthmatic inflammation. The cysteine leukotriene receptors, CysLT1 and CysLT2, are thus primary targets for anti-asthma drugs. A number of cysteinyl leukotrienes (including LTC4, LTD4, and LTE4) have been identified, and are known to function as inflammatory mediators as well as being potent smooth muscle contractile agents.
Leukotriene receptor antagonists (LTRAs) reduce the effect of allergic inflammation and athsma by blocking cysteine leukotriene activity. Several CysLT antagonists, such as montelukast, zafirlucast, and pranlukast, are currently used in the treatment of asthma.
For Academic pricing please login or contact us at discoverysciences@invitrogen.com.
